Clinical Trial Update: Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for rhHNS via an IDDD in MPS IIIA patients reports safety and tolerability data across ascending dose and dose frequency in Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis

Drugs mentioned

• rhHNS (recombinant human iduronidase? (Note: rhHNS refers to a recombinant human heparan/N-sulfoglucosaminidase surrogate; if specific generic name is not provided, set as null))

Snippet

Sponsor: Shire | Conditions: Mucopolysaccharidosis (MPS) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-12-12